Non-Lupus Full-House Glomerulonephritis Following COVID-19: A Rare Case of DNAJB9-Negative Fibrillary GN

Scritto il 14/11/2026
da Brian Nan

Kidney Med. 2026 Jul 25;8(12):101482. doi: 10.1016/j.xkme.2026.101482. eCollection 2026 Dec.

ABSTRACT

We report a novel case of fibrillary glomerulonephritis occurring just after coronavirus disease 2019 infection, presenting as non-lupus full-house immune complex glomerulonephritis and achieving complete renal recovery with cyclophosphamide-based therapy. A 74-year-old man with atrial fibrillation, ischemic cardiomyopathy, hypertension, and type 2 diabetes developed rapidly progressive kidney failure following mild acute respiratory syndrome coronavirus 2 infection. Laboratory evaluation revealed nephrotic-range proteinuria, hematuria, hypocomplementemia, and progressive acute kidney injury requiring initiation of kidney replacement therapy. Kidney biopsy demonstrated diffuse proliferative immune complex-mediated glomerulonephritis with full-house immunofluorescence staining and organized nonbranching fibrils on electron microscopy. Congo red and DNAJB9 staining were negative, consistent with an atypical, DNAJB9-negative fibrillary glomerulopathy rather than classic lupus nephritis or fibrillary glomerulonephritis. The patient was treated with intravenous cyclophosphamide using the Euro-Lupus protocol and a tapering course of glucocorticoids, resulting in discontinuation of kidney replacement therapy, normalization of serum creatinine, resolution of proteinuria, and recovery of complement levels. This case expands the spectrum of coronavirus disease 2019-associated glomerular disease and suggests that cyclophosphamide may be effective in select cases of postinfectious fibrillary glomerulopathy.

PMID:43032452 | PMC:PMC13762962 | DOI:10.1016/j.xkme.2026.101482